By Jemimah Wellington, JKNewsMedia Reporter
ADVANCEMENT IN cardiac care is unfolding inside a Cornell University laboratory, where a Nigerian PhD student, Aminat Ibrahim, is engineering a heart implant that could redefine global treatment.
Her medical innovation is designed to ease the burden of lifelong medication and may soon transform cardiac treatment worldwide.
The young lady. Aminat Ibrahim, a doctoral researcher in biomedical engineering, leads a research initiative developing next-generation heart valves capable of mimicking natural human tissue.
With the bioprosthetic, she aims to solve a critical challenge: the long-term complications and prohibitive costs associated with mechanical heart implants, especially in developing countries.
Her work also targets the urgent need for safer, more affordable treatments for heart disease, the world’s leading cause of death.
The condition has seen a sharp rise among younger populations in low- and middle-income nations.
Experts even cite poor healthcare access, late diagnosis, and lifestyle changes as key factors fuelling the crisis.
Mechanical valves currently used in patients often trigger clotting, which leads to stroke or death.
As a result, recipients are prescribed blood-thinning medication for life. But for those living in poverty, daily access to such drugs is far from guaranteed.
“Most of these patients must take blood-thinning medication for the rest of their lives,” said Ibrahim.
“But in a country where people struggle to afford basic needs, how can they manage the cost of daily medication?” She added that the high cost of aftercare often forces patients to stop treatment, with fatal consequences.
The motivation behind her mission is deeply personal. Raised in Nigeria, she recalled witnessing the silent toll of undiagnosed heart conditions and remembers the sudden loss of a close family friend to a heart attack.
Her experience was later echoed during a clinical internship in the United States, where similar cases exposed the global scale of the crisis.
With her research team, Ibrahim is developing an implant with a surface engineered to attract the patient’s own cells.
This approach significantly reduces the chances of rejection and clotting, potentially eliminating the need for anticoagulants.
“Our goal is to create a device that the body can accept as its own,” she explained. “If successful, this could eliminate the need for blood thinners, making treatment safer and more affordable.” The team has already achieved successful laboratory results and is currently conducting animal trials.
In many parts of the world, the cost of post-operative care remains a barrier more daunting than the surgery itself. “I have seen families sell everything they own for a single heart procedure,” she said. “But some patients still don’t survive—not because of surgical complications, but because they can’t afford aftercare.”
Ibrahim said she believes this technology must be accessible, not exclusive. “This technology should not be a privilege for the wealthy alone,” she said. “It should be available to everyone, regardless of their financial background,” she adds.
“From rigorous testing to regulatory hurdles, the path to market is long. Yet, I remain determined. My goal is not just to publish research that sits on a shelf, I want to see this innovation saving lives in hospitals around the world,” she stressed.
